Compare VYX & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | KURA |
|---|---|---|
| Founded | 1881 | 2014 |
| Country | United States | United States |
| Employees | 13500 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 841.6M |
| IPO Year | N/A | 2015 |
| Metric | VYX | KURA |
|---|---|---|
| Price | $6.56 | $11.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $13.67 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $6.02 | $5.45 |
| 52 Week High | $14.67 | $12.49 |
| Indicator | VYX | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 70.82 |
| Support Level | $6.21 | $8.80 |
| Resistance Level | $7.26 | $11.17 |
| Average True Range (ATR) | 0.42 | 0.59 |
| MACD | -0.12 | 0.16 |
| Stochastic Oscillator | 12.78 | 86.05 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.